Source of Informations

Here are some key points about leukemia


Leukemia (British spelling: leukaemia ) is cancer of the blood or bone marrow (which produces blood cells). A person who has leukemia suffers from an abnormal production of blood cells, generally leukocytes (white blood cells).

People sometimes confuse leukemia and lymphoma. Leukemia is a cancer of the blood, lymphoma is cancer of the lymphatic system (lymph glands). The word Leukemia comes from the Greek leukos which means “white” and aima which means “blood”.

The DNA of immature blood cells, mainly white cells, becomes damaged in some way. This abnormality causes the blood cells to grow and divide chaotically. Normal blood cells die after a while and are replaced by new cells which are produced in the bone marrow. The abnormal blood cells do not die so easily, and accumulate, occupying more and more space. As more and more space is occupied by these faulty blood cells there is less and less space for the normal cells – and the sufferer becomes ill. Quite simply, the bad cells crowd out the good cells in the blood.

Contents of this article:

Function of the bone marrow
Types of leukemia
Symptoms of leukemia
What causes leukemia?
Treatments for leukemia
Fast facts on leukemia
Here are some key points about leukemia. More detail and supporting information is in the main article.
Leukemia is cancer of the white blood cells. White blood cells help your body fight infection.
There are about 54,270 new cases of leukemia in the US each year.
Around 24,450 people die from leukemia per year in the US.
There are about 20,830 new cases of acute myeloid leukemia (AML) and 10,460 deaths from AML in the US each year, most cases are adults.
Leukemia is the seventh leading cause of cancer death in the United States.
Approximately 1.5% of men and women will be diagnosed with leukemia at some point during their lifetime.
Compared to other cancers, leukemia is relatively rare.
Although leukemia is among the most common childhood cancers, it most often occurs in older adults.
Leukemia is slightly more common in men than women.
People with leukemia have many treatment options, and treatment for leukemia can often control the disease and its symptoms.
In order to better understand what goes on we need to have a look at what the bone marrow does.

Function of the bone marrow
The bone marrow is found in the inside of bones. The marrow in the large bones of adults produces blood cells. Approximately 4% of our total bodyweight consists of bone marrow.

Leukemia cells
There are two types of bone marrow: 1. Red marrow, made up mainly of myeloid tissue. 2. Yellow marrow, made up mostly of fat cells. Red marrow can be found in the flat bones, such as the breast bone, skull, vertebrae, shoulder blades, hip bone and ribs. Red marrow can also be found at the ends of long bones, such as the humerus and femur.

White blood cells (lymphocytes), red blood cells and platelets are produced in the red marrow. Red blood cells carry oxygen, white blood cells fight diseases. Platelets are essential for blood clotting. Yellow marrow can be found in the inside of the middle section of long bones.

If a person loses a lot of blood the body can convert yellow marrow to red marrow in order to raise blood cell production.

White blood cells, red blood cells and platelets exist in plasma – Blood plasma is the liquid component of blood, in which the blood cells are suspended.

Types of leukemia
Chronic and Acute

Experts divide leukemia into four large groups, each of which can be Acute, which is a rapidly progressing disease that results in the accumulation of immature, useless cells in the marrow and blood, or Chronic, which progresses more slowly and allows more mature, useful cells to be made. In other words, acute leukemia crowds out the good cells more quickly than chronic leukemia.

Lymphocytic and Myelogenous

Leukemias are also subdivided into the type of affected blood cell. If the cancerous transformation occurs in the type of marrow that makes lymphocytes, the disease is called lymphocytic leukemia. A lymphocyte is a kind of white blood cell inside your vertebrae immune system. If the cancerous change occurs in the type of marrow cells that go on to produce red blood cells, other types of white cells, and platelets, the disease is called myelogenous leukemia.

To recap, there are two groups of two groups – four main types of leukemia, as you can see in the illustration below:

Diagram of the types of leukemia
Acute Lymphocytic Leukemia (ALL), also known as Acute Lymphoblastic Leukemia – This is the most common type of leukemia among young children, although adults can get it as well, especially those over the age of 65. Survival rates of at least five years range from 85% among children and 50% among adults. The following are all subtypes of this leukemia: precursor B acute lymphoblastic leukemia, precursor T acute lymphoblastic leukemia, Burkitt’s leukemia, and acute biphenotypic leukemia.

Chronic Lymphocytic Leukemia (CLL) – This is most common among adults over 55, although younger adults can get it as well. CLL hardly ever affects children. The majority of patients with CLL are men, over 60%. 75% of treated CLL patients survive for over five years. Experts say CLL is incurable. A more aggressive form of CLL is B-cell prolymphocytic leukemia.

Acute Myelogenous Leukemia (AML) – AML is more common among adults than children, and affects males significantly more often than females. Patients are treated with chemotherapy. 40% of treated patients survive for over 5 years. The following are subtypes of AMS – acute promyelocytic leukemia, acute myeloblastic leukemia, and acute megakaryoblastic leukemia.

Researchers from the Memorial Sloan-Kettering Cancer Center reported in the March 2012 issue of NEJM (New England Journal of Medicine that they identified a series of genetic mutations in people with AML. They explained that their findings may help doctors to more accurately predict patient outcomes, as well as choosing therapies they are most likely to respond to.

Chronic Myelogenous Leukemia (CML) – The vast majority of patients are adults. 90% of treated patients survive for over 5 years. Gleevec (imatinib) is commonly used to treat CML, as well as some other drugs. Chronic monocytic leukemia is a subtype of CML.

Symptoms of leukemia
Blood clotting is poor – As immature white blood cells crowd out blood platelets, which are crucial for blood clotting, the patient may bruise or bleed easily and heal slowly – he may also develop petechiae (a small red to purple spot on the body, caused by a minor hemorrhage).
Affected immune system – The patient’s white blood cells, which are crucial for fighting off infection, may be suppressed or not working properly. The patient may experience frequent infections, or his immune system may attack other good body cells.
Anemia – As the shortage of good red blood cells grows the patient may suffer from anemia – this may lead to difficult or labored respiration (dyspnea) and pallor (skin has a pale color caused by illness).
Other symptoms – Patients may also experience nausea, fever, chills, night sweats, flu-like symptoms, and tiredness. If the liver or spleen becomes enlarged the patient may feel full and will eat less, resulting in weight loss. Headache is more common among patients whose cancerous cells have invaded the CNS (central nervous system).
Precaution – As all these symptoms could be due to other illnesses. A diagnosis of leukemia can only be confirmed after medical tests are carried out.
What causes leukemia?
Experts say that different leukemias have different causes. The following are either known causes, or strongly suspected causes:

Artificial ionizing radiation
Viruses – HTLV-1 (human T-lymphotropic virus) and HIV (human immunodeficiency virus)
Benzene and some petrochemicals
Alkylating chemotherapy agents used in previous cancers
Maternal fetal transmission (rare)
Hair dyes
Genetic predisposition – some studies researching family history and looking at twins have indicated that some people have a higher risk of developing leukemia because of a single gene or multiple genes.
Down syndrome – people with Down syndrome have a significantly higher risk of developing leukemia, compared to people who do not have Down syndrome. Experts say that because of this, people with certain chromosomal abnormalities may have a higher risk.
Electromagnetic energy – studies indicate there is not enough evidence to show that ELF magnetic (not electric) fields that exist currently might cause leukemia. The IARC (International Agency for Research on Cancer) says that studies which indicate there is a risk tend to be biased and unreliable.
Recent developments on leukemia from MNT news
Breastfeeding linked with lower risk of childhood leukemia
The benefits of breastfeeding are reiterated in a new systematic review and meta-analysis published in JAMA Pediatrics that reports an association between breastfeeding and lower risk of childhood leukemia.
Avocado compound holds promise for treating leukemia
According to research published in the journal Cancer Research, there is a compound in avocados – called avocatin B – that holds promise for a new treatment for AML.
Could low vitamin D increase the risk of leukemia?
Many cases of leukemia across the globe may be caused by vitamin D deficiency as a result of low sunlight exposure. This is the conclusion of a new study published in PLOS One.
Treatments for leukemia
As the various types of leukemias affect patients differently, their treatments depend on what type of leukemia they have. The type of treatment will also depend on the patient’s age and his state of health.

In order to get the most effective treatment the patient should get treatment at a center where doctors have experience and are well trained in treating leukemia patients. As treatment has improved, the aim of virtually all health care professionals should be complete remission – that the cancer goes away completely for a minimum of five years after treatment.

Treatment for patients with acute leukemias should start as soon as possible – this usually involves induction therapy with chemotherapy, and takes place in a hospital.

When a patient is in remission he will still need consolidation therapy or post induction therapy. This may involve chemotherapy, as well as a bone marrow transplant (allogeneic stem cell transplantation).

If a patient has Chronic Myelogenous Leukemia (CML) his treatment should start as soon as the diagnosis is confirmed. He will be given a drug, probably Gleevec (imatinib mesylate), which blocks the BCR-ABL cancer gene. Gleevec stops the CML from getting worse, but does not cure it. There are other drugs, such as Sprycel (dasatinib) and Tarigna (nilotinb), which also block the BCR-ABL cancer gene. Patients who have not had success with Gleevec are usually given Sprycel and Tarigna. All three drugs are taken orally. A bone marrow transplant is the only current way of curing a patient with CML. The younger the patient is the more likely the transplant will be successful.

Synribo (omacetaxine mepesuccinate) was approved by the FDA, on 26th October 2012, for the treatment of chronic myelogenous leukemia (CML) in adult patients who had been treated with at least two drugs, but whose cancer continued to progress. Resistance to medications is common in CML. Synribo is an alkaloid from Cephalotaxus harringtonia which inhibits proteins that trigger the development of cancerous cells. The drug is administered subcutaneously.

Patients with Chronic Lymphocytic Leukemia (CLL) may not receive any treatment for a long time after diagnosis. Those who do will normally be given chemotherapy or monoclonal antibody therapy. Some patients with CLL may benefit from allogeneic stem cell transplantation (bone marrow transplant).

Rabbit antibodies help Leukemia patients – scientists from Virginia Commonwealth University reported in the journal Bone Marrow Transplantation (July 2012 issue) that rabbit antibodies can improve survival and reduce the occurrence of relapses in patients with leukemia and myelodysplasia who are receiving a stem transplant from an unrelated donor.

Leukemia patients’ own T-cells achieve remission for over two years – patients who were infused with their own T-cells after they had been genetically altered to fight cancer tumors stayed in full remission for over 24 months. Researchers from the Perelman School of Medicine at the University of Pennsylvania presented their findings at the American Society of Hematology’s Annual Meeting and Exposition in December 2012. All those who took part in the human study had advanced cancers – ten of them had chronic lymphocytic leukemia, and two children had acute lymphoblastic leukemia.

All leukemia patients, regardless of what type they have or had, will need to be checked regularly by their doctors after the cancer has gone (in remission). They will undergo exams and blood tests. The doctors will occasionally test their bone marrow. As time passes and the patient continues to remain free of leukemia the doctor may decide to lengthen the intervals between tests.

New leukemia immune cell therapy shows promise – New findings on cell therapy to treat leukemia bring more encouraging news of the promise that this experimental area of cancer treatment holds for patients for whom conventional approaches do not work. The research was published in the journal Science Translational Medicine in February 2014.

Recent developments on leukemia treatment from MNT news
‘New drug target for leukemia identified’
A new drug target for treating leukemia has been identified as part of the largest ever genetic analysis of tumor growth in childhood blood cancer.
Leukemia cells can kill each other, study finds
The discovery of a rare human antibody has pointed to a way of getting leukemia cells to kill each other, according to research published in Proceedings of the National Academy of Sciences.